Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CVKD

Cadrenal Therapeutics Inc

Nov 30 • 04:00PM ET

0.4600

Dollar change -0.0068
Percentage change -1.46	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.04	Insider Own	58.17%	Shs Outstand	11.63M	Perf Week	-11.52%
Market Cap	5.99M	Forward P/E	-	EPS next Y	-	Insider Trans	1.75%	Shs Float	5.45M	Perf Month	4.31%
Income	-12.22M	PEG	-	EPS next Q	-0.07	Inst Own	8.49%	Short Float / Ratio	0.45% / 0.49	Perf Quarter	-40.26%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Interest	0.02M	Perf Half Y	-67.49%
Book/sh	0.67	P/B	0.68	EPS next Y	-	ROA	-248.00%	Target Price	3.00	Perf Year	-
Cash/sh	0.70	P/C	0.66	EPS next 5Y	-	ROE	-323.09%	52W Range	0.40 - 6.75	Perf YTD	-88.83%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-139.72%	52W High	-93.19%	Beta	-
Dividend %	-	Quick Ratio	16.46	Sales past 5Y	-	Gross Margin	-	52W Low	16.46%	ATR	0.07
Employees	3	Current Ratio	16.46	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	42.96	Volatility	15.31% 14.18%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	9.75%	Profit Margin	-	Rel Volume	0.53	Prev Close	0.47
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	50.26K	Price	0.46
Recom	1.00	SMA20	-0.99%	SMA50	-16.71%	SMA200	-59.89%	Volume	26,514	Change	-1.46%

Today 04:15PM	Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023 (PR Newswire)
Nov-09-23 09:00AM	Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update (PR Newswire) -5.38%
Oct-16-23 08:38AM	Innovation Takes Center Stage: Florida's Life Sciences Leaders Shine at BioFlorida Conference (PR Newswire)
Oct-09-23 04:15PM	Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference (PR Newswire)
Sep-05-23 08:00AM	Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress (PR Newswire)
08:00AM	Loading…
Aug-30-23 08:00AM	Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS) (PR Newswire)
Aug-28-23 04:15PM	Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-10-23 09:00AM	Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update (PR Newswire)
Aug-01-23 09:00AM	Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseases (PR Newswire)
Jul-24-23 09:00AM	Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors (PR Newswire) -11.65%
Jul-14-23 03:02PM	Cadrenal Therapeutics Announces Closing of $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules (PR Newswire) -18.37%
Jul-12-23 03:17PM	Cadrenal Therapeutics Announces $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules (PR Newswire) +29.31%
Jun-28-23 06:23AM	The 3 Hottest IPOs to Buy Before They Soar (InvestorPlace)
Jun-01-23 09:00AM	Cadrenal Therapeutics to Participate in the 2023 BIO International Convention in Boston (PR Newswire)
May-10-23 09:00AM	Cadrenal Therapeutics Provides First Quarter 2023 Corporate Update (PR Newswire)
04:30PM	Loading…
May-09-23 04:30PM	Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2023 Investor Conference (PR Newswire)
Mar-30-23 09:00AM	Cadrenal Therapeutics Provides Fiscal Year 2022 Corporate Update (PR Newswire) +8.53%
Mar-09-23 09:00AM	Cadrenal Therapeutics Recognizes National Kidney Month with Goal to Advance Tecarfarin for Severely Underserved Patient Population (PR Newswire) -7.69%
Feb-08-23 09:00AM	Cadrenal Therapeutics to Ring the NASDAQ Stock Market Closing Bell on February 8, 2023 (PR Newswire) -9.26%
Feb-06-23 09:00AM	Cadrenal Therapeutics to Participate in the 2023 BIO CEO & Investor Conference (PR Newswire) -6.25%
Feb-01-23 09:00AM	Cadrenal Therapeutics Announces Formation of Scientific Advisory Board (PR Newswire)
Jan-24-23 02:11PM	Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public Offering (PR Newswire) -18.37%
Jan-23-23 11:39AM	What's Going On With Cadrenal Therapeutics Stock Today (Benzinga)
08:30AM	Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation (PR Newswire)
Jan-20-23 09:31AM	Cadrenal Therapeutics Announces Pricing of Initial Public Offering (IPO) (PR Newswire)

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang Pham on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MURPHY JOHN RAYMOND	Director	Oct 05	Buy	0.69	2,669	1,842	614,792	Oct 06 05:32 PM
MURPHY JOHN RAYMOND	Director	Oct 04	Buy	0.70	17,331	12,132	612,123	Oct 06 05:32 PM
Pham Quang X	CEO and Chairman	Sep 05	Buy	0.90	40,000	36,188	3,410,000	Sep 06 03:28 PM
Pham Quang X	CEO and Chairman	Sep 01	Buy	0.91	70,000	63,945	3,370,000	Sep 05 06:05 AM
MURPHY JOHN RAYMOND	Director	Mar 21	Buy	1.39	10,000	13,900	594,792	Mar 22 04:01 PM
MURPHY JOHN RAYMOND	Director	Mar 16	Buy	1.67	20,000	33,398	574,792	Mar 16 05:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CVKD

Cadrenal Therapeutics Inc

Upgrade your FINVIZ experience